1. Academic Validation
  2. Discovery and characterization of a cell-permeable, small-molecule c-Abl kinase activator that binds to the myristoyl binding site

Discovery and characterization of a cell-permeable, small-molecule c-Abl kinase activator that binds to the myristoyl binding site

  • Chem Biol. 2011 Feb 25;18(2):177-86. doi: 10.1016/j.chembiol.2010.12.013.
Jingsong Yang 1 Nino Campobasso Mangatt P Biju Kelly Fisher Xiao-Qing Pan Josh Cottom Sarah Galbraith Thau Ho Hong Zhang Xuan Hong Paris Ward Glenn Hofmann Brett Siegfried Francesca Zappacosta Yoshiaki Washio Ping Cao Junya Qu Sophie Bertrand Da-Yuan Wang Martha S Head Hu Li Sheri Moores Zhihong Lai Kyung Johanson George Burton Connie Erickson-Miller Graham Simpson Peter Tummino Robert A Copeland Allen Oliff
Affiliations

Affiliation

  • 1 Oncology Research and Development, GlaxoSmithKline, 1250 South Collegeville Road, Collegeville, PA 19426, USA. [email protected]
Abstract

c-Abl kinase activity is regulated by a unique mechanism involving the formation of an autoinhibited conformation in which the N-terminal myristoyl group binds intramolecularly to the myristoyl binding site on the kinase domain and induces the bending of the αI helix that creates a docking surface for the SH2 domain. Here, we report a small-molecule c-Abl activator, DPH, that displays potent enzymatic and cellular activity in stimulating c-Abl activation. Structural analyses indicate that DPH binds to the myristoyl binding site and prevents the formation of the bent conformation of the αI helix through steric hindrance, a mode of action distinct from the previously identified allosteric c-Abl inhibitor, GNF-2, that also binds to the myristoyl binding site. DPH represents the first cell-permeable, small-molecule tool compound for c-Abl activation.

Figures
Products
  • Cat. No.
    Product Name
    Description
    Target
    Research Area
  • HY-12070
    99.20%, Bcr-Abl Activator